PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcimmBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Immunology
 
BMC Immunol. 2012; 13: 28.
Published online Jun 6, 2012. doi:  10.1186/1471-2172-13-28
PMCID: PMC3459731
Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer
Donghai Yang,#1,2 Xin Fan,#1 Ping Yin,1 Qiang Wen,1 Feng Yan,1 Sibo Yuan,2 Bin Liu,1 Guohong Zhuang,corresponding author1 and Zhongchen Liucorresponding author2
1Anti-Cancer Research Center, Medical College, Xiamen University, Xiamen, China
2Zhongshan Hospital, Xiamen University, Xiamen, China
corresponding authorCorresponding author.
#Contributed equally.
Donghai Yang: donghai19/at/sina.com; Xin Fan: 250165096/at/qq.com; Ping Yin: yinping/at/xmzsh.com; Qiang Wen: wq_zero/at/163.com; Feng Yan: yanfeng/at/xmzsh.com; Sibo Yuan: yuansibo/at/xmzsh.com; Bin Liu: binbinyouli689/at/qq.com; Guohong Zhuang: zhuangguohong/at/yahoo.com.cn; Zhongchen Liu: zyj.tt/at/163.com
Received November 4, 2011; Accepted May 18, 2012.
Abstract
Background
Decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor (TNFR) superfamily, is associated with anti-tumor immunity suppression. It is highly expressed in many tumors, and its expression can be regulated by the MAPK/MEK/ERK signaling pathway. The MAPK/MEK/ERK pathway has been reported to be a regulator in tumor occurrence, development and clonal expansion. External-signal regulated kinase (ERK) is a vital member of this pathway.
Results
The expression of DcR3 and ERK1/2 in tumor tissues of gastric cancer patients was significantly higher than the non-cancerous group (P < 0.05). There was no statistical difference among tumor tissues from patients with different ages or gender, and even of different differentiation (P > 0.05). However, in patients with stage I gastric cancer, the DcR3 and ERK1/2 levels were significantly lower than patients with more advanced stages.
Conclusions
DcR3 and ERK1/2 play a vital role in the development of gastric cancer, and they may be new markers for indicating the efficiency of gastric cancer treatment in the future.
Articles from BMC Immunology are provided here courtesy of
BioMed Central